Desde há mais de vinte anos que as atenções se viraram para os corona vírus. O que foi feito?
Vejamos a história das patentes registadas sobre essa investigação.
Ouvir um vídeo é o que todos fazemos e a maioria acredita no que ouve. Dissecar um vídeo é mais complicado.
Decidi apresentar aqui o vídeo que quase todos conhecem, este legendado em Português (a tradução é fiável). Eis o vídeo em questão é longo mas vale a pena.
Para que possam segui-lo apresento-vos os registos oficiais das patentes com as suas datas; os que entendem de biologia molecular poderão comparar as diferentes sequências genómicas e tirar as ilações convenientes.
Jan 28, 2000 - Pfizer Inc. a 1ª patente registada de uma vacina que diz respeito à proteina S (spike) do vírus. Isto para o corona vírus canino que é um dos corona vírus
April 19, de 2002 - Universidade da Carolina do Norte em Chapel Hill aqui regista-se a patente de como produzir o corona vírus em laboratório, as células permissivas para a sua replicação, a possibilidade de fazer vacinas ou de modificar o tropismo do vírus para qualquer mucosa pela simples manipulação da proteína S.
Passo a transcrever: "Importantly, recombinant coronavirus VRPs [virus replication particle (s)] can be readily targeted to other mucosal surfaces mammalian species such as swine by simple replacements in the S glycoprotein gene, which has been shown to determine tissue and species tropism (Delmas, et al. (1992) Nature 357:417-420; Kuo, et al. (2000) J. Virol. 74:1393-1406; Sánchez, et al. (1999) J. Virol. 73:7607-7618; Tresnan, et al. (1996) J. Virol. 70:8669-8674). For these reasons, coronavirus VRPs and vectorsprovide a valuable approach for the production of combination vaccines in a variety of mammalian hosts."
Também consta desta patente a vacina "The methods can comprise inoculating the vertebrate with the recombinant virus, e.g., by introducing the virus into the vertebrate subcutaneously, intradermally, intramuscularly, orally or in ovum."
Investigação financiada desde 1999 que levou à produção pelo NIAID (National Institute of Allergy and Infectious Diseases) de um corona vírus com tropismo para as células pulmonares, capaz de produzir infecção, isto é, um SARS. Por coincidência em 2002 começa o SARS-COV.
Em 2001 já foi feito um relatório alertando para o facto de o coronavírus estar a ser "visto" como uma potente arma biológica.
(apresentada em Apr 12, 2004, patente recusada mas aceite em 2007 por motivos que não pretendo mencionar aqui), mantida em segredo, segundo se diz...
Apr 28, 2004 - Sequoia Pharmaceuticals, Inc. apresenta o tratamento para o vírus da patente anterior
Neste Post abstenho-me de comentários, cada um dos que me seguem já têm conhecimentos suficientes para analisar este assunto.
Podem também ler o Dossier Fauci sobre o SARS-Cov-2 muito esclarecedor.
Deixo aqui as inúmeras patentes e outros acontecimentos, por ordem de data:
NIAID Grant AI 23946 leading to patent U.S. 7,279,327 “Methods for Producing Recombinant Coronavirus” Filed 2002 and issued 2007 https://patents.google.com/patent/US7279327B2/ru The paper first published from the NIAID grant is https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC7109931&blobtype=pdf
Pfizer files U.S. Patent 6,372,224 on a vaccine for the S-protein on coronavirus November 14, 2000 which was abandoned April 2010 making it public domain.
Work focused on CoV association with cardiomyopathy (see above)
Early reference to the “emergence” of CoV as a respiratory pathogen in https://link.springer.com/content/pdf/10.1007%2F978-1-4615-1899-0_91.pdf
Ralph Baric AI23946 and GM63228 from the National Institutes of Health actively working recombinant CoV
National Institute of Health, Allergy and Infectious diseases. “Reverse Genetics with a Coronavirus Infectious cDNA Construct.” 4/1/2001-3/31/005 $1.0 million total costs/yr. RS Baric, PI
Asia CoV SARS outbreak
April 25, 2003 CDC Patent filed and ultimately becomes US7,220,852 (the patent on the RNA sequence) and 7,776,521 (the patent on the testing methodology. These patents give the U.S. Department of Health and Human Services the ability to control the commercial exploitation of SARS coronavirus.
Dr. Anthony Fauci appointed to the Bill and Melinda Gates Foundation’s Global Grand Challenges Scientific Advisory Board (served through 2010).
April 28, 2003 Sequoia Pharmaceuticals $953K for pathogen response and patent US7,151,163 https://www.sbir.gov/node/305319
July 21, 2003 Ralph Baric’s team (using AI23946 and GM63228) file U.S. Patent 7,618,802 which issued on November 17, 2009. https://patents.google.com/patent/US7618802B2
Dana Farber Cancer Institute files U.S. Patent 7,750,123 on a monoclonal antibody to neutralize SARS CoV. This research is supported by several NIH grants including National Institutes of Health Grants A128785, A148436, and A1053822.
January 6, 2004 – SARS and Bioterrorism linked at Bioterrorism and Emerging Infectious Diseases: antimicrobials, therapeutics and immune modulators. https://tks.keystonesymposia.org/index.cfm?e=web.meeting.program&meetingid=706
At this conference, the term “The New Normal” was introduced by Merck
FAUCI AND BARIC start making money!!! National Institutes of Health, Allergy and Infectious Diseases. SARS Reverse Genetics. AI059136-01. $1.7 million total costs, RS Baric, PI. 10% effort. 4/1/04- 3/31/09. The project develops a SARS-CoV full length infectious cDNA, the development of SARS-CoV replicon particles expressing heterologous genes, and seeks to adapt SARS-CoV to mice, producing a pathogenic mouse model for SARS-CoV infection. Fauci/COVID-19 Dossier CC-BY-NC-SA Dr. David E. Martin 18 National Institutes of Health, Allergy and Infectious D
National Institutes of Health, Allergy and Infectious Diseases. R01. Remodeling the SARS Coronavirus Genome Regulatory Network. RS Baric, PI 10% effort. 7/1/04-6/30/09. $2.1 million November 22, 2004 University of Hong Kong patents SARS associated spike protein on CoV and pursues patent US 7,491,489
DARPA gets in on the game Synthetic Coronaviruses. Biohacking: Biological Warfare Enabling Technologies, June 2005. Washington, DC. DARPA/MITRE sponsored event. Invited Speaker
Review timeline from https://www.youtube.com/watch?v=rO_EeYB0i0U and https://www.davidmartin.world/wp-content/uploads/2020/04/20APRBotWslides.pdf
Biodefense Grant U54 AI057157 commences with $10,189,682 to UNC Chapel Hill https://taggs.hhs.gov/Detail/AwardDetail?arg_awardNum=U54AI057157&arg_ProgOfficeCode=104
Biodefense Grant U54 AI057157 continues with $5,448,656 to UNC Chapel Hill (non-competitive grant from NIAID)
Biodefense Grant U54 AI057157 continues with $8,747,142 to UNC Chapel Hill (non-competitive grant from NIAID)
Patent issuance for SARS coronavirus patents peak post the Asia outbreak at 391 issued patents.
August 6, 2010, Moderna (prior to its establishment) files U.S. Patent 9,447,164 which attracted the investment of (and “inventorship” for) venture capitalists at Flagship Ventures. This patent grew out of the work of Dr. Jason P. Schrum of Harvard Medical School supported by National Science Foundation Grant #0434507. While the application claims priority to August 2010, the application didn’t get finalized until October, 2015. On November 4, 2015, the USPTO issued a non-final rejection on this original patent rejecting all claims. https://www.nsf.gov/awardsearch/showAward?AWD_ID=0434507 with reference to the grant funding in https://molbio.mgh.harvard.edu/szostakweb/publications/Szostak_pdfs/Schrum_et_al_JACS_2009.pdf
Crucell joined the Janssen Pharmaceutical Companies of Johnson & Johnson in February taking with it all of its SARS technology. Biodefense Grant U54 AI057157 continues with $7,344,820 to UNC Chapel Hill (non-competitive grant from NIAID)
MERS isolated in Egypt Biodefense Grant U54 AI057157 continues with $7,627,657 to UNC Chapel Hill (non-competitive grant from NIAID)
Biodefense Grant U54 AI057157 continues with $7,226,237 to UNC Chapel Hill (non-competitive grant from NIAID)
April 23, 2014, Moderna files patent on nucleic acid vaccine with Patents US9872900 and US10022435 Fauci/COVID-19 Dossier CC-BY-NC-SA 2015
Moderna signs a vaccine development agreement with NIAID and executes it with the lead on the mRNA-1273 lead developer and inventor Guiseppe Ciaramella. https://www.documentcloud.org/documents/6935295-NIH-Moderna-Confidential-Agreements.html
NIH through Scripps Institute and Dartmouth College file patent application WO 2018081318A1 “Prefusion Coronavirus Spike Proteins and their Use” disclosing mRNA technology that overlaps (and is used in tandem with) Moderna’s technology. https://patents.google.com/patent/WO2018081318A1/en Lead Inventor Barney Scott Graham was well known to Moderna as he’s the person at NIH that Moderna “e-mailed” to get the sequence for SARS CoV-2 according to Moderna’s report here (“In January 2020, once it was discovered that the infection in Wuhan was caused by a novel coronavirus, Bancel quickly emailed Dr. Barney Graham, deputy director of the Vaccine Research Center at the National Institutes of Health, asking him to send the genetic sequence for the virus.”) https://www.wsws.org/en/articles/2020/05/26/vacc-m26.html In addition, co-inventor Jason McLellan worked with Graham on a vaccine patent jointly owned with the Chinese government filed in Australia in 2013 https://patents.google.com/patent/AU2014231357A1/en?inventor=Jason+MCLELLAN.
August – Sanofi buys Protein Science Corp with considerable SARS patent holdings
June – Sanofi buys Ablynx with considerable SARS patent holdings
March, https://wyss.harvard.edu/news/sherlock-biosciences-licenses-wyss-technology-to-createaffordable-molecular-diagnostics/ funded by Open Philanthropy – the same organization that would be the financial sponsor of the Event 201 “table-top” exercise that laid out the entire “pandemic” plan in October 2019.
NOTA: Regista-se um vírus manipulado, criado, em laboratório. NÃO É PASSÍVEL DE PATENTE um vírus que surge espontaneamente na natureza. O que a natureza cria não pode ser patenteado.
Para completar tudo isto, eis a publicação de 12-07-2021 da OMS